CardioComm Solutions, Inc. Secures Exclusive Distribution Rights in Quebec for ECG Medical Devices
CardioComm Solutions, Inc. (TSXV: EKG) has secured exclusive distribution rights in Quebec for TZ Medical Inc.'s ECG monitoring devices. This agreement enhances access to long-term continuous ECG monitoring devices for Canadians. The deal focuses on the Trident Pro and Trident Nano devices, which are integrated with CardioComm's Global Electrocardiogram Management software (GEMS™).
CardioComm plans to integrate these devices with new software releases, GEMS™ Holter and GEMS Long Term Continuous Monitoring, scheduled for 2025. This integration aims to meet the growing demand for combined 14 to 30-day Holter and Event monitoring. The exclusive rights in Quebec will facilitate hardware tendering processes with provincial hospitals using or considering GEMS™.
CardioComm Solutions, Inc. (TSXV: EKG) ha ottenuto i diritti di distribuzione esclusiva in Quebec per i dispositivi di monitoraggio ECG di TZ Medical Inc. Questo accordo migliora l'accesso ai dispositivi di monitoraggio ECG continuo a lungo termine per i canadesi. L'accordo si concentra sui dispositivi Trident Pro e Trident Nano, che sono integrati con il software di gestione dell'elettrocardiogramma globale di CardioComm (GEMS™).
CardioComm prevede di integrare questi dispositivi con i nuovi rilasci software, GEMS™ Holter e GEMS Long Term Continuous Monitoring, programmati per il 2025. Questa integrazione mira a soddisfare la crescente domanda di monitoraggio combinato Holter e Event di 14-30 giorni. I diritti esclusivi in Quebec faciliteranno i processi di gara per l'hardware con gli ospedali provinciali che utilizzano o considerano GEMS™.
CardioComm Solutions, Inc. (TSXV: EKG) ha obtenido los derechos de distribución exclusivos en Quebec para los dispositivos de monitoreo ECG de TZ Medical Inc. Este acuerdo mejora el acceso a los dispositivos de monitoreo ECG continuo a largo plazo para los canadienses. El acuerdo se centra en los dispositivos Trident Pro y Trident Nano, que están integrados con el software de gestión del electrocardiograma global de CardioComm (GEMS™).
CardioComm planea integrar estos dispositivos con nuevas versiones de software, GEMS™ Holter y GEMS Long Term Continuous Monitoring, programadas para 2025. Esta integración tiene como objetivo satisfacer la creciente demanda de monitorización combinada Holter y Event de 14 a 30 días. Los derechos exclusivos en Quebec facilitarán los procesos de licitación de hardware con los hospitales provinciales que utilizan o están considerando GEMS™.
CardioComm Solutions, Inc. (TSXV: EKG)는 TZ Medical Inc.의 ECG 모니터링 장치에 대한 독점 배급권을 퀘벡에서 확보했습니다. 이 계약은 캐나다인들에게 장기 지속 ECG 모니터링 장치에 대한 접근성을 향상시킵니다. 이 협약은 CardioComm의 글로벌 심전도 관리 소프트웨어(GEMS™)와 통합된 Trident Pro 및 Trident Nano 장치에 중점을 두고 있습니다.
CardioComm은 2025년으로 예정된 GEMS™ Holter 및 GEMS Long Term Continuous Monitoring의 새로운 소프트웨어 출시와 함께 이 장치들을 통합할 계획입니다. 이 통합은 14일에서 30일간의 홀터 및 이벤트 모니터링에 대한 증가하는 수요를 충족하는 것을 목표로 하고 있습니다. 퀘벡의 독점 권리는 GEMS™를 사용하는 병원과 협의 중인 하드웨어 입찰 과정을 용이하게 할 것입니다.
CardioComm Solutions, Inc. (TSXV: EKG) a obtenu les droits de distribution exclusifs au Québec pour les dispositifs de surveillance ECG de TZ Medical Inc. Cet accord améliore l'accès aux dispositifs de surveillance ECG continue à long terme pour les Canadiens. L'accord se concentre sur les dispositifs Trident Pro et Trident Nano, qui sont intégrés avec le logiciel de gestion électrocardiographique mondial de CardioComm (GEMS™).
CardioComm prévoit d'intégrer ces dispositifs avec de nouvelles versions logicielles, GEMS™ Holter et GEMS Long Term Continuous Monitoring, prévues pour 2025. Cette intégration vise à répondre à la demande croissante de surveillance combinée Holter et Événement de 14 à 30 jours. Les droits exclusifs au Québec faciliteront les processus d'appel d'offres matériels avec les hôpitaux provinciaux utilisant ou envisageant GEMS™.
CardioComm Solutions, Inc. (TSXV: EKG) hat die exklusiven Vertriebsrechte für die ECG-Überwachungsgeräte von TZ Medical Inc. in Quebec gesichert. Diese Vereinbarung verbessert den Zugang zu langfristigen kontinuierlichen ECG-Überwachungsgeräten für Kanadier. Der Vertrag konzentriert sich auf die Geräte Trident Pro und Trident Nano, die mit der globalen Elektrokardiogramm-Management-Software (GEMS™) von CardioComm integriert sind.
CardioComm plant, diese Geräte mit neuen Softwareversionen, die für 2025 vorgesehen sind, GEMS™ Holter und GEMS Long Term Continuous Monitoring, zu integrieren. Ziel dieser Integration ist es, der wachsenden Nachfrage nach kombinierter 14- bis 30-tägiger Holter- und Ereignisüberwachung gerecht zu werden. Die exklusiven Rechte in Quebec werden die Beschaffungsprozesse für Hardware mit den Provinzkrankenhäusern, die GEMS™ verwenden oder in Betracht ziehen, erleichtern.
- Secured exclusive distribution rights for ECG monitoring devices in Quebec
- Integration of TZM devices with CardioComm's GEMS™ software
- Planned release of new software products in 2025 to meet growing demand
- Potential for increased sales through facilitated hardware tendering processes with Quebec hospitals
- None.
Deal enhances access to long term continuous ECG monitoring devices for Canadians
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software and hardware solutions, is pleased to announce an exclusivity agreement for the Province of Quebec for the sale and distribution of TZ Medical Inc. ("TZM") ECG monitoring devices used for standard and extended Holter and cardiac arrhythmia monitoring.
CardioComm has had a long-standing relationship with the hardware manufacturer, Oregon-based TZM, and is a non-exclusive distributor for TZM's ECG monitoring medical devices in Canada and the US. Of specific interest are the TZM Trident Pro and Trident Nano devices that are integrated with CardioComm's class-leading Global Electrocardiogram Management software (GEMSTM), which is widely licensed by North American clinics and hospitals. The addition of Quebec exclusivity will facilitate hardware tendering processes with provincial hospitals that use or are considering a license for use of GEMSTM.
CardioComm will integrate the TZM Trident Pro and Nano devices with GEMSTM Holter and GEMS Long Term Continuous Monitoring (GEMS LTCM), two new CardioComm software releases planned for 2025. CardioComm's GEMS LTCM will be positioned to meet the growing demand for combined, 14 to 30 day, Holter and Event monitoring. The new devices will join CardioComm's growing product lines, including the HeartCheckTM branded home ECG devices, the Body-by-GEMSTM multiple bio-signal monitoring solutions, and the GEMSTM-based products for clinics and hospitals.
To learn more about CardioComm's products and for further updates please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221458
FAQ
What exclusive distribution rights has CardioComm Solutions (EKGGF) secured in Quebec?
What new software products is CardioComm Solutions (EKGGF) planning to release in 2025?
How will the Quebec exclusivity agreement benefit CardioComm Solutions (EKGGF)?
What is the target market for CardioComm Solutions' (EKGGF) new GEMS LTCM software?
